Chimeric Therapeutics Issues 325 Warrants in Second Tranche of Convertible Notes Placement

Overview of Chimeric Therapeutics’ Capital Structure and Recent Financing

Chimeric Therapeutics Limited, an ASX-listed biopharmaceutical company, continues to advance its capital raising efforts throughout 2026 to support its therapeutic development programs. The issuance of 325 warrants on 17 July 2026 marks a continuation of a phased capital raise initiated earlier in the year, illustrating the company’s strategic use of convertible instruments to secure funding.

This warrant issuance is directly tied to the convertible notes financing arrangement that received shareholder approval at an extraordinary general meeting held on 17 April 2026. This approval authorized the company to issue securities in multiple tranches, providing flexibility in capital deployment while managing prevailing market conditions. The combination of convertible notes with attached warrants is a common biotech financing approach, offering investors debt-like instruments alongside potential equity upside through warrant conversion rights.

Details on the Second Tranche Warrant Issuance and Prior Announcements

The 325 warrants issued represent the second tranche outlined in the Appendix 3B announcement dated 19 March 2026. This earlier disclosure detailed a proposed placement involving various securities, and the current issuance confirms Chimeric Therapeutics is progressing with the transaction structure as planned. The company has indicated that an additional 1,300 warrants remain to be issued to complete the approved transaction framework from the April 2026 meeting.

The announcement did not specify the issue price or detailed terms of the warrants, focusing instead on the mechanics of issuance. Notably, the warrants were issued without cash consideration, bundled with convertible notes rather than issued separately, signifying that their value is integrated with the underlying convertible note security. This structure grants holders the right to acquire shares at predetermined exercise prices, supplementing their convertible note investment.

Unquoted Securities Portfolio and Shareholder Dilution Implications

Following the recent issuance, Chimeric Therapeutics’ unquoted securities portfolio includes 700 warrants (CHMAAL), 14,666,683 options expiring 31 December 2030 at an exercise price of $0.50, 500,000 options expiring 31 March 2029 at $0.60, 250,000 options expiring 10 October 2028 at $0.80, and 2,961,331 options with various expiry dates and exercise prices. Additionally, the company has 350 convertible notes outstanding and 72,280 performance rights.

The scale of these unquoted securities relative to the 57,909,156 quoted ordinary shares presents a significant potential dilution risk for existing shareholders. The aggregate options and warrants represent contingent claims on future equity, while convertible notes add complexity by converting into ordinary shares upon meeting specific conditions or investor election. Stakeholders should monitor conversion and exercise activity closely, as accelerated actions could materially increase share count and impact earnings per share.

Regulatory Approval and Shareholder Authority for the Financing Structure

The warrant issuance on 17 July 2026 was conducted under a regulatory framework explicitly approved by shareholders at the extraordinary general meeting on 17 April 2026. This meeting authorized the board to issue convertible notes and attached warrants in multiple tranches. This governance process ensures that the capital raise underwent formal shareholder scrutiny prior to execution. The ASX notification confirms the second tranche warrant issuance aligns with this approved transaction.

Utilizing extraordinary general meetings for significant capital raises is standard among ASX-listed companies, providing transparency and shareholder control over potentially dilutive transactions. By July 2026, shareholders had endorsed the financing structure nearly four months earlier, allowing management operational flexibility while maintaining accountability.

Warrant Characteristics and Their Role in Convertible Notes

The warrants issued are unquoted securities (CHMAAL) and do not trade on the ASX. While specific exercise prices or expiry dates were not disclosed, these warrants serve as incentives attached to convertible notes, a common practice in biotech financings to enhance investor returns without immediate cash outlay.

For investors, these warrants offer additional exposure to share price appreciation by enabling subscription at predetermined exercise prices. For Chimeric Therapeutics, this structure provides a future equity claim without upfront cash payments. The remaining 1,300 warrants to be issued suggest a phased capital raise, potentially managing shareholder dilution or aligning with corporate milestones.

Outstanding Warrants and Capital Raise Completion

Chimeric Therapeutics has disclosed that 1,300 warrants remain outstanding to fully complete the transaction framework approved in April 2026 and initially announced in March 2026. This totals approximately 1,625 warrants authorized across all tranches (325 issued plus 1,300 pending). The phased issuance offers management timing flexibility to assess market conditions and capital requirements before deploying the remaining warrants.

No specific timeline or conditions triggering the issuance of the remaining warrants were provided. Investors should monitor future company announcements for updates, as further issuances will increase unquoted securities outstanding and may cause incremental dilution to shareholders. The pace of these issuances could provide insights into the company’s operational progress and funding needs.

Impact on Quoted Share Capital and Market Positioning

At the time of this warrant issuance, Chimeric Therapeutics had 57,909,156 ordinary fully paid shares quoted on the ASX (CHM), representing the primary equity security. The recent warrant issuance did not immediately affect the quoted share count, which remains stable. However, as options are exercised, warrants converted, convertible notes matured, and performance rights vested, the total quoted shares are expected to increase.

Investors should consider potential dilution when evaluating future earnings per share or market capitalization relative to the company’s capital raising activities. The ongoing issuance of unquoted securities in 2026 reflects an active fundraising phase likely supporting development milestones and operational expenses.

Context Within the Biotech Sector’s Financing Trends

Chimeric Therapeutics’ phased warrant issuance aligns with financing trends observed across ASX-listed biotech companies in 2026. Biotech firms often face long development timelines and significant capital needs before revenue generation, making convertible financing structures attractive. These instruments combine debt-like features with equity upside through warrants and conversion rights, allowing capital raising while deferring dilution.

The Australian biotech sector has shown sustained investor interest in convertible securities with attached warrants, especially among companies approaching clinical or regulatory milestones. Chimeric Therapeutics’ approach reflects confidence in future value creation that could justify warrant exercise or note conversion at favorable terms. The staged issuance acknowledges shifting capital needs and strategic priorities as development progresses.

Summary of On-Issue Securities and Key Metrics

Following the 17 July 2026 issuance, the company’s unquoted securities include 700 CHMAAL warrants, 14,666,683 CHMAAI options expiring 31 December 2030 at $0.50 exercise price, 500,000 CHMAAJ options expiring 31 March 2029 at $0.60, 250,000 CHMAAH options expiring 10 October 2028 at $0.80, 2,961,331 CHMAY options with various expiry dates and exercise prices, 350 CHMAAK convertible notes, and 72,280 CHMAB performance rights. This extensive unquoted portfolio dwarfs the 57,909,156 quoted ordinary shares, highlighting the contingent equity claims embedded in the capital structure.

This layered structure reflects the company’s reliance on sophisticated investors familiar with complex securities and the biotech industry’s preference for instruments that delay full equity dilution while raising capital. Performance rights typically represent management incentives tied to milestones, and their vesting alongside option exercises and note conversions will likely accelerate share count growth as clinical development advances.

Investor Considerations and Monitoring Recommendations

Investors should closely monitor several developments: announcements regarding issuance of the remaining 1,300 warrants; conversions of the 350 outstanding convertible notes; exercise or expiry of large option tranches such as the 14.7 million CHMAAI options at $0.50; and vesting of performance rights. Changes in management incentives or capital allocation strategies may also influence issuance timing.

Additionally, tracking Chimeric Therapeutics’ clinical progress, regulatory interactions, and future capital raising activities is critical. Successful milestone achievements could support warrant exercise and note conversion, while delays or setbacks might reduce the value of contingent securities. Investors should remain vigilant regarding shifts in the company’s strategic direction and capital deployment plans.